5 Array BioPharma Analyst Ratings, Earnings, Dividends and Insider Trades | $ARRY | NASDAQ:ARRY | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Array BioPharma Company Profile (NASDAQ:ARRY) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Array BioPharma (NASDAQ:ARRY) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)Consensus Rating:Buy (Score: 2.67)Consensus Price Target: $6.48 (28.57% upside) Analysts' Ratings History for Array BioPharma (NASDAQ:ARRY) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/19/2014ZacksDowngradeOutperform -> Neutral$5.40View 1/21/2014ZacksUpgradeNeutral -> Outperform$6.00View 12/3/2013ZacksDowngradeOutperform -> Neutral$6.40View 11/4/2013ZacksUpgradeNeutral -> Outperform$5.80View 11/1/2013BMO Capital MarketsBoost Price TargetMarket Perform$3.00 -> $4.00View 8/9/2013Jefferies GroupBoost Price TargetBuy$7.00 -> $8.00View 8/9/2013Stifel NicolausBoost Price TargetBuy$7.00 -> $8.00View 7/24/2013Leerink SwannReiterated RatingPositiveView 6/3/2013Jefferies GroupReiterated RatingBuy$6.50 -> $7.00View 5/8/2013Jefferies GroupBoost Price TargetBuy$6.00 -> $6.50View 3/25/2013Piper JaffrayUpgradeNeutral -> Overweight$4.00 -> $7.00View 12/19/2012Wells Fargo & Co.Initiated CoverageOutperformView 10/26/2012Brean CapitalInitiated CoverageBuy$10.00View 8/15/2012Leerink SwannUpgradeMarket Perform -> Outperform$4.00 -> $8.00View 8/15/2012Jefferies GroupReiterated RatingBuyView 6/5/2012Jefferies GroupReiterated RatingBuy (N/A)View (Data available from 3/8/2012 forward) Earnings History for Array BioPharma (NASDAQ:ARRY)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView 10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView 8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView 5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView 2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView 10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView 8/13/2012($0.11)($0.09)ViewN/AView 4/30/2012($0.16)($0.11)ViewN/AView 1/30/2012($0.12)($0.06)ViewN/AView 5/2/2011($0.25)($0.20)ViewN/AView 1/31/2011($0.28)($0.23)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Array BioPharma (NASDAQ:ARRY)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Array BioPharma (NASDAQ:ARRY)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View 9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View 8/2/2013John R MooreVPSell75,384$7.02$529,195.68View 7/23/2013John R MooreVPSell5,000$6.50$32,500.00View (Data available from 1/1/2013 forward) About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company's drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614. Headlines: (3/3) Array BioPharma Provides Clinical Update On ARRY-502 For Asthma At Scientific Meeting (3/5) Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed ... (2/20) Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients ... (2/18) Array BioPharma To Present At The RBC Capital Markets Global Healthcare And Cowen Annual Healthcare Conferences (2/6) Array BioPharma To Present At The Leerink Swann Global Healthcare Conference Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: ARRY CUSIP: 04269X10 Key Metrics: Previous Close: $5.0450 Day Moving Average: $4.9688200 Day Moving Average: $5.4312 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $632.3MCurrent Quarter EPS Consensus Estimate: $-0.69 EPS Additional Links: View ARRY on Google FinanceView ARRY on Yahoo FinanceView ARRY's Company Profile on ReutersSearch for Array BioPharma Inc. on Google Array BioPharma (NASDAQ:ARRY) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.